ARVN Arvinas, Inc. - 8-K

Item 7.01    Regulation FD Disclosure.

Representatives of Arvinas, Inc. (the "Company") intend to use a presentation (the "Investor Presentation") at various meetings with investors, analysts or others from time to time, including in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, beginning Tuesday, June 2, 2026. The Investor Presentation may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing, or other means. A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01    Other Events.

Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. As previously disclosed, in the second quarter of 2026, the Company announced that it had completed dose escalation enrollment of the Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring Kirsten rat sarcoma ("KRAS") G12D mutations. The Company is planning to complete this Phase 1 monotherapy dose escalation clinical trial and share clinical data in 2026. The Company plans to seek an out-licensing agreement for any additional clinical trials, including dose expansion or combination clinical trials, for ARV-806.

The Company continues to believe that its cash, cash equivalents and marketable securities as of March 31, 2026, will enable the Company to fund its planned operating expenses and capital expenditure requirements into the second half of 2028.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number

Description of Exhibit

99.1

Company Presentation , for use beginning June 2 , 2026

104

Cover Page Interactive Data File (formatted as Inline XBRL)

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the Company's plans with respect to ARV-806, including any potential out-licensing agreement for additional clinical trials of ARV-806 . All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made by the Company as a result of various risks and uncertainties, including the risk factors discussed in the “Risk Factors” sections contained in the Company’s quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this filing reflect the Company’s current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.